| Features: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Caffeic Acid Phenethyl Ester (CAPE) — CAPE is a propolis-derived phenolic ester and bioactive honeybee-hive constituent with pleiotropic anti-inflammatory and antineoplastic signaling effects. It is best classified as a natural polyphenolic small molecule and experimental adjunct candidate rather than an approved anticancer drug. Standard abbreviations include CAPE; common chemical naming includes caffeic acid phenethyl ester and phenethyl caffeate. CAPE is most strongly associated with poplar-type propolis chemistry, but it is also available as an ingredient in some dietary-supplement products. Current oncology relevance remains preclinical to early translational, with growing interest in chemosensitization and radiosensitization but no established cancer indication. Primary mechanisms (ranked):
Bioavailability / PK relevance: Oral translation is constrained by poor aqueous solubility, limited absorption, esterase-sensitive disposition, and substantial hydrolysis to caffeic acid in vivo. Rat PK work supports measurable exposure after oral dosing, but CAPE analogues with improved permeability outperform parent CAPE. Formulation strategies are therefore mechanistically relevant for systemic use. In-vitro vs systemic exposure relevance: Many direct anticancer studies use roughly 10–60 μM exposure, with some effects emerging near or above this range; those concentrations may exceed or stress the upper edge of practical systemic exposure with simple oral delivery. Tumor-directed claims should therefore be weighted more heavily when supported by in vivo xenograft, radiosensitization, or formulation-enabled data rather than cell culture alone. Clinical evidence status: Predominantly preclinical with in vitro, xenograft, and ex vivo support; small translational signals exist for radiosensitization/radioprotection concepts, but there is no established oncology trial program or approved cancer use for CAPE itself. CAPE — Cancer vs Normal Cell Pathway Map
TSF legend: P: 0–30 min; R: 30 min–3 hr; G: >3 hr |
| Source: |
| Type: |
| A radiosensitizer is an agent that makes cancer cells more sensitive to the damaging effects of radiation therapy. By using a radiosensitizer, clinicians aim to enhance the effectiveness of radiation treatment by either increasing the damage incurred by tumor cells or by interfering with the cancer cells’ repair mechanisms. This can potentially allow for lower doses of radiation, reduced side effects, or improved treatment outcomes. Pathways that help Radiosensitivity: downregulating HIF-1α, increase SIRT1, Txr List of Natural Products with radiosensitizing properties: -Curcumin:modulate NF-κB, STAT3 and has been shown in preclinical studies to enhance the effects of radiation by inhibiting cell survival pathways. -Resveratrol: -EGCG: -Quercetin: -Genistein: -Parthenolide: How radiosensitizers inhibit the thioredoxin (Trx) system in cellular contexts. Notable radiosensitizers, including: -gold nanoparticles (GNPs), -gold triethylphosphine cyanide ([Au(SCN) (PEt3)]), -auranofin, ceria nanoparticles (CONPs), -curcumin and its derivatives, -piperlongamide, -indolequinone derivatives, -micheliolide, -motexafin gadolinium, and -ethane selenide selenidazole derivatives (SeDs) |
| 5754- | CAPE, | Rad, | The radiosensitizing effect of Caffeic Acid Phenethyl Ester in breast cancer is dependent on p53 status |
| - | in-vivo, | BC, | MDA-MB-231 |
| 5758- | CAPE, | PBG, | Caffeic acid phenethyl ester and therapeutic potentials |
| - | Review, | Var, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:395 Target#:1107 State#:% Dir#:2
wNotes=0 sortOrder:rid,rpid